Literature DB >> 16432024

Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients.

Xiaofen Zhong1, Zufeng Guo, Huanghao Yang, Lisheng Peng, Yong Xie, Tin-Yau Wong, Sik-To Lai, Zhihong Guo.   

Abstract

The 3a protein of severe acute respiratory syndrome (SARS)-associated coronavirus is expressed and transported to the plasma membrane in tissue cells of infected patients. Its short N-terminal ectodomain was found to elicit strong humoral responses in half of the patients who had recovered from SARS. The ectodomain-specific antibodies from the convalescent-phase plasma readily recognized and induced destruction of 3a-expressing cells in the presence of the human complement system, demonstrating their potential ability to provide immune protection by recognizing and eliminating SARS coronavirus-infected cells that express the target protein. In addition, when coupled to a carrier protein, the ectodomain peptide elicited 3a-specific antibodies in mice and rabbit at high titres. These results showed that the N terminus of the 3a protein is highly immunogenic and elicits potentially protective humoral responses in infected patients. Therefore, the short extracellular domain may be a valuable immunogen in the development of a vaccine for infectious SARS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432024     DOI: 10.1099/vir.0.81078-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.

Authors:  Baojing Lu; Ling Tao; Ting Wang; Zhenhua Zheng; Bao Li; Ze Chen; Yi Huang; Qinxue Hu; Hanzhong Wang
Journal:  Clin Vaccine Immunol       Date:  2008-11-05

2.  Significance of coronavirus mutants in feces and diseased tissues of cats suffering from feline infectious peritonitis.

Authors:  Niels C Pedersen; Hongwei Liu; Kimberly A Dodd; Patricia A Pesavento
Journal:  Viruses       Date:  2009-08-26       Impact factor: 5.048

3.  Autophagy: more than a nonselective pathway.

Authors:  Fulvio Reggiori; Masaaki Komatsu; Kim Finley; Anne Simonsen
Journal:  Int J Cell Biol       Date:  2012-05-15

Review 4.  Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.

Authors:  Yee-Joo Tan; Seng Gee Lim; Wanjin Hong
Journal:  Antiviral Res       Date:  2006-06-06       Impact factor: 5.970

5.  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.

Authors:  Luis Enjuanes; Marta L Dediego; Enrique Alvarez; Damon Deming; Tim Sheahan; Ralph Baric
Journal:  Virus Res       Date:  2007-04-09       Impact factor: 3.303

Review 6.  SARS coronavirus accessory proteins.

Authors:  Krishna Narayanan; Cheng Huang; Shinji Makino
Journal:  Virus Res       Date:  2007-11-28       Impact factor: 3.303

7.  Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs.

Authors:  Ben Sorum; Sonali S Mali; Christopher M Hoel; David M Kern; Savitha Sridharan; Jonathan P Remis; Daniel B Toso; Abhay Kotecha; Diana M Bautista; Stephen G Brohawn
Journal:  Nat Struct Mol Biol       Date:  2021-06-22       Impact factor: 15.369

Review 8.  The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis.

Authors:  Ruth McBride; Burtram C Fielding
Journal:  Viruses       Date:  2012-11-07       Impact factor: 5.048

Review 9.  Accessory proteins of SARS-CoV and other coronaviruses.

Authors:  Ding Xiang Liu; To Sing Fung; Kelvin Kian-Long Chong; Aditi Shukla; Rolf Hilgenfeld
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

10.  The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function.

Authors:  Chak-Ming Chan; Ho Tsoi; Wing-Man Chan; Shenyu Zhai; Ching-On Wong; Xiaoqiang Yao; Wood-Yee Chan; Stephen Kwok-Wing Tsui; Ho Yin Edwin Chan
Journal:  Int J Biochem Cell Biol       Date:  2009-05-04       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.